MRNA EBITDA | Moderna, Inc.

Moderna, Inc. (MRNA) EBITDA

2026-06-30: Basis Reported; EBITDA -$759M; Operating income (m); Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA -$1.33B; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$791M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$209M; Operating income (m); Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2016-12-31 to 2026-06-30
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$759M	(m)	(m)	(m)	-523.45%	$37.00M*	-$526.00M*	$93.00M	$651.00M	(m)	$15.00M
2026-03-31	Reported	-$1.33B	(m)	(m)	(m)	-342.42%	$62.00M	-$630.00M	$955.00M	$649.00M	(m)	$9.00M
2025-12-31	Reported	-$791M	(m)	(m)	(m)	-116.67%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$209M	(m)	(m)	(m)	-20.57%	$33.00M*	-$847.00M*	$207.00M	$801.00M	(m)	$13.00M
2025-06-30	Reported	-$851M	(m)	(m)	(m)	-599.30%	$3.00M*	-$919.00M*	$119.00M	$700.00M	(m)	$7.00M
2025-03-31	Reported	-$1.01B	(m)	(m)	(m)	-937.04%	$117.00M	-$1.04B	$90.00M	$856.00M	(m)	$7.00M
2024-12-31	Reported	-$1.19B	(m)	(m)	(m)	-122.88%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$19M	(m)	(m)	(m)	-1.02%	$151.00M*	-$1.57B*	$514.00M	$1.14B	(m)	$8.00M
2024-06-30	Reported	-$1.32B	(m)	(m)	(m)	-548.96%	$182.00M*	-$1.27B*	$115.00M	$1.22B	(m)	$0.00
2024-03-31	Reported	-$1.23B	(m)	(m)	(m)	-737.13%	$196.00M	-$989.00M	$96.00M	$1.06B	(m)	$10.00M
2023-12-31	Reported	$209M	(m)	(m)	(m)	7.44%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$1.77B	(m)	(m)	(m)	-96.45%	$140.00M*	-$1.60B*	$2.24B	$1.16B	(m)	$1.67B
2023-06-30	Reported	-$1.78B	(m)	(m)	(m)	-516.57%	$234.00M*	-$915.00M*	$731.00M	$1.15B	(m)	-$369.00M
2023-03-31	Reported	-$288M	(m)	(m)	(m)	-15.47%	$113.00M	-$1.23B	$792.00M	$1.13B	(m)	-$384.00M
2022-12-31	Reported	$1.66B	(m)	(m)	(m)	32.65%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	$1.28B	(m)	(m)	(m)	38.02%	$89.00M*	$252.00M*	$1.10B	$820.00M	(m)	$174.00M
2022-06-30	Reported	$2.52B	(m)	(m)	(m)	53.13%	$87.00M*	$304.00M*	$1.38B	$710.00M	(m)	$277.00M
2022-03-31	Reported	$4.31B	(m)	(m)	(m)	70.99%	$132.00M	$2.76B	$1.02B	$554.00M	(m)	$572.00M
2021-12-31	Reported	$5.49B	(m)	(m)	(m)	76.11%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	$3.63B	(m)	(m)	(m)	73.01%	$99.00M*	$3.28B*	$722.00M	$521.00M	(m)	$219.00M
2021-06-30	Reported	$3.13B	(m)	(m)	(m)	71.91%	$30.00M*	$4.06B*	$750.00M	$421.00M	(m)	$283.00M
2021-03-31	Reported	$1.28B	(m)	(m)	(m)	66.13%	$35.00M	$2.97B	$193.00M	$401.00M	(m)	$39.00M
2020-12-31	Reported	-$268M	(m)	(m)	(m)	-46.94%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$227M	(m)	(m)	(m)	-144.59%	$19.00M*	$893.00M*	$0.00	$344.00M	(m)	$1.00M
2020-06-30	Reported	-$114M	(m)	(m)	(m)	-170.15%	$19.00M*	-$24.00M*	$0.00	$152.00M	(m)	$0.00
2020-03-31	Reported	-$124M	(m)	(m)	(m)	-1550.00%	$6.00M	-$106.00M	$0.00	$115.00M	(m)	$0.00
2019-12-31	Reported	-$120.93M	(m)	(m)	(m)	-860.42%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$123.46M	(m)	(m)	(m)	-724.30%	$6.71M*	-$107.09M*	(m)	$119.64M	(m)	-$178.00K
2019-06-30	Reported	-$136.21M	(m)	(m)	(m)	-1041.11%	$10.59M*	-$108.58M*	(m)	$128.31M	(m)	-$324.00K
2019-03-31	Reported	-$134.33M	(m)	(m)	(m)	-838.22%	$7.59M	-$144.27M	(m)	$130.41M	(m)	-$24.00K
2018-12-31	Reported	-$145.68M	(m)	(m)	(m)	-411.28%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$79.32M	(m)	(m)	(m)	-189.95%	$26.14M*	-$80.21M*	(m)	$109.05M	(m)	$0.00
2018-06-30	Reported	-$91.12M	(m)	(m)	(m)	-315.81%	$34.08M*	-$48.25M*	(m)	$104.48M	(m)	$158.00K
2018-03-31	Reported	-$72.25M	(m)	(m)	(m)	-248.80%	$31.91M	-$111.39M	(m)	$90.12M	(m)	$0.00
2017-12-31	Reported	(m)	-$41.83M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	(m)	-$67.87M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Reported	(m)	-$94.19M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-03-31	Reported	(m)	-$65.46M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$2.86B	(m)	(m)	(m)	-147.27%	$192.00M	-$1.87B	$868.00M	$3.13B	(m)	$54.00M
2024-12-31	Reported	-$3.76B	(m)	(m)	(m)	-116.19%	$1.05B	-$3.00B	$1.46B	$4.54B	(m)	-$46.00M
2023-12-31	Reported	-$3.62B	(m)	(m)	(m)	-52.89%	$707.00M	-$3.12B	$4.69B	$4.84B	(m)	$772.00M
2022-12-31	Reported	$9.77B	(m)	(m)	(m)	50.71%	$400.00M	$4.98B	$5.42B	$3.29B	(m)	$1.21B
2021-12-31	Reported	$13.53B	(m)	(m)	(m)	73.24%	$284.00M	$13.62B	$2.62B	$1.99B	(m)	$1.08B
2020-12-31	Reported	-$732M	(m)	(m)	(m)	-91.16%	$68.00M	$2.03B	$8.00M	$1.37B	(m)	$3.00M
2020-09-30	Rolling	(m)	-$618.56M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$514.32M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$536.03M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$515M	(m)	(m)	(m)	-855.35%	$32.00M	-$459.00M	$0.00	$496.00M	(m)	-$1.00M
2019-12-31	Rolling	(m)	-$546.67M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$569.14M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$524.20M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$477.50M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$388.4M	(m)	(m)	(m)	-287.56%	$105.77M	-$330.87M	$0.00	$454.08M	(m)	$326.00K
2018-12-31	Rolling	(m)	-$413.27M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$302.06M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$284.12M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$281.30M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$248.82M	(m)	(m)	(m)	-120.89%	$58.40M	-$331.48M	(m)	$410.46M	(m)	-$80.00K
2017-12-31	Rolling	(m)	-$269.36M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	-$208.66M	(m)	(m)	(m)	-192.50%	$33.14M	$66.73M	(m)	$274.72M	(m)	$1.04M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Revolution Medicines, Inc. (RVMD)	United States	$42.805B	-22.69
BIOGEN INC. (BIIB)	United States	$33.427B	19.60
EXELIXIS, INC. (EXEL)	United States	$14.358B	16.15
NEUROCRINE BIOSCIENCES INC (NBIX)	United States	$14.131B	24.25
HALOZYME THERAPEUTICS, INC. (HALO)	United States	$13.083B	21.59
Twist Bioscience Corp (TWST)	United States	$11.540B	-47.21
BIO-TECHNE Corp (TECH)	United States	$11.379B	74.68
REPLIGEN CORP (RGEN)	United States	$10.755B	185.31
Krystal Biotech, Inc. (KRYS)	United States	$10.210B	45.56
Kymera Therapeutics, Inc. (KYMR)	United States	$9.631B	-31.69